check_circleStudy Completed

Pseudomonas

Bayer Identifier:

Trial_1172

ClinicalTrials.gov Identifier:

Not Available

EudraCT Number:

Not Available

EU CT Number:

Not Available
Anti-Pseudomonas treatment in patients with cystic fibrosis

Trial purpose

Please see attached Study Results Summary below.

Key Participants Requirements

Sex

Both

Age

8 - 25 Years
  • -

  • -

Trial summary

Enrollment Goal
45
Trial Dates
March 1988 - February 1992
Phase
Phase 3
Could I Receive a placebo
N/A
Products
Cipro (Ciprofloxacin, BAYQ3939)
Accepts Healthy Volunteer
N/A

Trial design

Anti-Pseudomonas treatment in patients with cystic fibrosis "optimal" 2 week inpatient "intensive treatment" consisting of ceftazidime with amikacin (AK) i.v. plus AK p.i. (by inhalation) subsequent 3-month "maintenance treatment" with ciprofloxacin p.o. prospective randomized study with and without additional use of AK p.i.
Trial Type
Interventional
Intervention Type
N/A
Trial Purpose
N/A
Allocation
N/A
Blinding
N/A
Assignment
N/A
Trial Arms
N/A

Additional Information

Click here and search for drug information provided by the FDA.Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.Click here to find results for studies related to marketed products.